Related Experiment Video
Updated: Jun 19, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
1Disciplina de Endocrinologia, Departamento de Clínica Médica, Universidade Estadual de Campinas, Campinas, SP, Brazil. leticiamurro@uol.com.br.
Abstract:
Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...

